12:00 AM
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ACH-3102: Phase I started

Achillion began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single and multiple ascending-doses of oral...

Read the full 64 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >